Description:
Crisaborole is a novel PDE-4 inhibitor used as a nonsteroidal topical medication for the treatment of mild-to-moderate atopic dermatitis (eczema). Crisaborole selectively inhibits PDE-4B which mainly leads to inflammation. Tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines are also suppressed while crisaborole functioning.
- Molecular Weight: 251.048
- Molecular Formula: C14H10BNO3
Purity: 99%
Canonical SMILES:
B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O
InChI:
InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2
InChIKey: USZAGAREISWJDP-UHFFFAOYSA-N
- Appearance: White powder
- Application: the treatment of mild-to-moderate atopic dermatitis (eczema)
Synonyms:
AN2728; AN-2728; AN 2728; Crisaborole; Eucrisa; 4-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile
More details are to be found on supplier website
